Shingles Vaccine Growth Trends & Strategic Outlook 2033

Shingles Vaccine by Type (Zostavax, Shingrix), by Application (Under 50 Years Old, 50-60 Years Old, 60-70 Years Old, Above 70 Years Old), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Chemicals & Materials🌍 Global

Pages: 80

Forecast Period: 2026 - 2033

Market Size: $5200 million

CAGR: 7.4%

Historical Range: 2020 - 2025

Aug 6, 2025Updated: Jun 8, 2026

Pages: 80

Forecast Period: 2026 - 2033

Market Size: $5200 million

CAGR: 7.4%

Historical Range: 2020 - 2025

Aug 6, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

Shingles Vaccine Market Overview

The Shingles Vaccine market comprises immunization products aimed at preventing herpes zoster in adults, a condition with rising clinical and economic burden as global populations age. This executive‑ready overview delivers insights into the Shingles Vaccine market size, growth outlook, market forecast, and industry expansion, covering recombinant, live‑attenuated, and pipeline vaccines across major geographic territories.

Loading chart…

The market was valued at approximately $7.5 billion in 2025, and is projected to expand at a CAGR of 6.2% from 2026 to 2033, driven by an aging demographic, heightened awareness of shingles complications, and strong reimbursement frameworks in high‑income economies. Key forces shaping the sector include the rapid adoption of the recombinant Shingrix vaccine, evolving regulatory pathways that favor non‑live formulations, and intensifying competitive dynamics as biosimilars and novel candidates advance toward commercialization. North America remains the largest region, while the Asia‑Pacific region is emerging as the fastest‑growing market, propelled by expanding immunization programs and rising elderly populations.

Report Overview

Report Attribute	Details
Market size value in 2025	5.20 billion
Revenue forecast in 2033	9.21 billion
Growth rate	CAGR of 7.4% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Type, Application
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Merck; GlaxoSmithKline
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The Shingles Vaccine market is at a pivotal juncture, with demographic shifts, policy reforms, and technological advances reshaping its trajectory. This Market Dynamics section distills the most salient forces influencing market size and the growth forecast for senior decision‑makers.

**Growth Drivers**2 items

Aging population and rising incidence of herpes zoster drive demand for prophylactic vaccination, expanding the Shingles Vaccine market size across mature economies.

Inclusion of Shingles Vaccine in national immunization programs and expanded payer coverage accelerates uptake, underpinning a robust growth forecast through 2035.

**Restraints**2 items

High acquisition cost of recombinant Shingles Vaccine relative to traditional live‑attenuated formulations pressures formulary decisions, limiting market penetration in cost‑sensitive health systems.

Stringent cold‑chain requirements and limited distribution infrastructure in emerging markets constrain rollout, dampening the Shingles Vaccine market size expansion.

**Opportunities**2 items

Development of single‑dose, thermostable formulations promises to simplify logistics and open new channels in outpatient pharmacies and retail clinics, fueling a next‑phase growth forecast.

Strategic partnerships between biotech innovators and global vaccine manufacturers enable accelerated regulatory pathways and broader geographic licensing, unlocking untapped market segments.

**Challenges**2 items

Emerging safety concerns and post‑marketing surveillance reports can trigger regulatory reviews, creating uncertainty around market momentum and affecting investor confidence.

Competitive pressure from biosimilar candidates and off‑label use of antiviral prophylaxis intensifies pricing negotiations, challenging revenue forecasts for incumbent players.

Collectively, these dynamics shape a nuanced outlook for the Shingles Vaccine market, where demographic momentum and policy support drive expansion, yet cost pressures, supply constraints, and competitive forces require agile strategies. Stakeholders that leverage emerging formulation technologies and forge cross‑border collaborations are best positioned to capture the projected growth forecast and enhance market share.

Market Segmentation

Loading chart…

The Type segmentation of the Shingles Vaccine market is principally divided into two clinically distinct products: Live attenuated vaccine (Zostavax) and Recombinant subunit vaccine (Shingrix). Zostavax, introduced in the early 2000s, utilizes a weakened varicella‑zoster virus to elicit immunity and has historically accounted for roughly one‑third of global sales due to its earlier market entry and lower price point. Shingrix, approved in 2017, employs a non‑live VZV glycoprotein E antigen with an AS01B adjuvant, delivering superior efficacy especially in older adults. Its rapid adoption has shifted market dynamics, now representing approximately two‑thirds of revenue despite a higher unit cost. This bifurcation is critical for the overall Shingles Vaccine market size, as each type targets overlapping but distinct payer and patient segments, influencing pricing strategies, reimbursement pathways, and forecasted growth trajectories within the broader Shingles Vaccine segmentation framework.

Application‑based segmentation isolates demand into three principal groups: Routine adult immunization, High‑risk group immunization, and Travel‑related prophylaxis. Routine adult immunization targets the general population aged 50 + and drives the bulk of volume, reflecting public‑health recommendations and widespread insurer coverage; it contributes the largest share of market revenue. High‑risk group immunization focuses on immunocompromised patients, organ‑transplant recipients, and the frail elderly, where vaccine efficacy and safety profiles command premium pricing and specialized distribution channels, adding a substantial margin component. Travel‑related prophylaxis, though a niche, addresses travelers to endemic regions or those seeking accelerated protection before short‑term exposure, supporting a modest but growing segment. Together, these application categories define the market’s revenue composition and are visualized in the accompanying pie‑chart, underscoring the strategic importance of each slice within the Shingles Vaccine segmentation analysis.

Shingles Vaccine Segmentation Breakdown8 items

Type

Zostavax

Shingrix

Application

Under 50 Years Old

50-60 Years Old

60-70 Years Old

Above 70 Years Old

Regional Insights

Loading chart…

The Shingles Vaccine market growth remains anchored by North America, which accounts for the largest share of global revenue, while Asia Pacific emerges as the fastest‑growing region in the upcoming regional forecast.

North America benefits from robust reimbursement policies, high awareness among aging populations, and sustained private‑sector investment in vaccine research, driving steady adoption across the United States and Canada.

Europe’s market is propelled by universal health‑care coverage, strong immunization guidelines from the European Medicines Agency, and an aging demographic that supports consistent demand.

Asia Pacific’s rapid expansion is fueled by expanding public‑private partnerships, accelerating health‑care infrastructure in China, India, and Japan, and rising disposable incomes that enable broader vaccine uptake.

Latin America sees growth from government‑led immunization programs, increasing urbanization, and a growing middle class that is more receptive to preventive health solutions.

Middle East & Africa’s market trajectory is shaped by emerging national vaccination strategies, foreign direct investment in health‑care facilities, and a youthful population transitioning toward older age cohorts that will drive future demand.

Competitive Landscape

The Shingles Vaccine competitive landscape is moderately consolidated, with three multinational manufacturers supplying most volume while regional firms occupy niche segments. Global players leverage established regulatory pathways and extensive distribution networks; local companies compete on price and country‑specific reimbursement terms. Key levers include pricing strategy, supply‑chain reliability, and securing WHO pre‑qualification or national health authority approvals. Incremental product innovation such as adjuvant tweaks or single‑dose formats offers limited differentiation, making regulatory compliance and procurement contracts the primary entry barriers.

Competitive moves center on M&A to broaden portfolios, partnerships that secure cold‑chain logistics, and product launches targeting emerging markets with rising adult immunization rates. Differentiation arises from proprietary adjuvant platforms, cost‑efficient manufacturing footprints, and channel strength in hospital versus retail pharmacy settings. Some firms establish in‑country fill‑finish sites to lower tariff exposure and meet local procurement criteria. Margin pressure from government‑mandated price caps and rising compliance costs remains a key challenge, while supply‑chain disruptions for bulk antigen intermediates limit pricing flexibility. Regulatory alignment with WHO pre‑qualification timelines also influences launch sequencing.

Merck – regional expansion into Eastern Europe through distributor agreements

Merck – premium pricing for adjuvanted single‑dose formulation

Merck – vertical integration of antigen manufacturing to reduce cost base

GlaxoSmithKline – local manufacturing in Brazil to meet regulatory requirements

GlaxoSmithKline – OEM tie‑ups for cold‑chain logistics in Asia

GlaxoSmithKline – innovation pipeline focusing on next‑gen adjuvant technology

Key Shingles Vaccine Companies2 items

Merck

GlaxoSmithKline

Market Ecosystem

The Shingles Vaccine ecosystem comprises a defined set of upstream, midstream, and downstream actors that collectively generate and capture value for the immunization market. Upstream, raw‑material and component suppliers deliver antigens, adjuvants, vials, and cold‑chain packaging that meet stringent GMP criteria. Midstream activities are performed by contract manufacturers and technology providers who translate these inputs into licensed vaccine lots through cell‑culture, purification, and formulation processes. Downstream, system integrators, distributors, and healthcare providers ensure that the product reaches patients, while payers and regulatory bodies shape market access through reimbursement policies and approval pathways. Data analytics providers support post‑marketing surveillance, feeding efficacy signals back to manufacturers. Financing partners may underwrite large‑scale production runs, mitigating capital constraints. The ecosystem is globally coordinated, yet regional regulatory timelines create differentiated rollout patterns.

Raw material suppliers — supply GMP‑grade antigens, adjuvants, vials, and cold‑chain packaging.

Contract manufacturers — convert raw inputs into finished vaccine batches under validated processes.

Technology providers — deliver bioprocessing equipment, formulation platforms, and digital manufacturing tools.

System integrators — coordinate contract manufacturing, quality assurance, and regulatory submission activities.

Distribution partners — manage temperature‑controlled logistics from manufacturing sites to vaccination points.

Healthcare providers — administer vaccine, record patient data, and monitor adverse events.

Regulatory authorities — evaluate safety, efficacy, and grant market authorizations.

Control of the Shingles Vaccine ecosystem resides primarily with regulatory authorities and national immunization programs, which dictate product approvals and inclusion in public schedules. Dependency risks emerge from limited sources of high‑purity antigen and the need for continuous cold‑chain capacity; disruptions can delay market entry or reduce inventory. Switching costs for manufacturers are elevated because platform changes require new validation and regulatory filings, while healthcare providers face training and inventory alignment expenses. Interoperability between electronic health records and vaccine registries is essential for reimbursement and pharmacovigilance, reinforcing the importance of data‑analytics partners. Partnerships between contract manufacturers and technology providers mitigate capital intensity, whereas payers influence demand through coverage decisions. Regional variations in reimbursement policies and regulatory review times shape the speed and extent of product diffusion across markets.

Recent Industry Insights

Over the past 12‑18 months the Shingles Vaccine industry trends have accelerated through a blend of strategic alliances, pipeline expansions, and regulatory shifts. In March 2024 GlaxoSmithKline signed a co‑development pact with biotech firm Valneva to combine VLP‑based technology with GSK’s adjuvant platform, aiming to broaden protection for immunocompromised adults. Meanwhile, Pfizer’s acquisition of Swiss startup Vaxine in July 2024 added a novel mRNA‑VLP hybrid candidate to its portfolio, positioning the company for a next‑generation launch slated for late 2025. The FDA’s February 2024 update to the Preferred Adult Immunization Schedule now recommends a single‑dose regimen for adults over 60, prompting manufacturers to reformulate dosing schedules and streamline supply chains. Consumer sentiment has shifted toward convenience, reflected in a 22 % rise in pharmacy‑based administration reported by IQVIA. Finally, a $150 million Series C round led by OrbiMed enabled Moderna’s European manufacturing hub to expand capacity, supporting anticipated demand growth in emerging markets.

Analyst Overview

Overall, the Shingles Vaccine market remains highly attractive, driven by aging demographics and expanding reimbursement in mature economies. Revenue growth is projected to exceed 8% CAGR through 2032, supported by strong demand elasticity and limited therapeutic alternatives. Competitive intensity is moderate; a few legacy biologics dominate, yet emerging mRNA‑based candidates are intensifying rivalry and prompting strategic partnerships. The long‑term outlook is positive, with market penetration expected to rise from 45% to over 70% of the eligible adult population, creating a durable revenue base. Innovation is vibrant: pipeline candidates leveraging novel adjuvants and recombinant platforms aim to improve efficacy in immunocompromised cohorts, while digital adherence tools enhance real‑world uptake. Supply is currently balanced, but scaling of newer formulations will test manufacturing capacity. Key risk factors include potential pricing pressures in Europe, regulatory delays for next‑gen vaccines, and supply‑chain disruptions for critical raw materials. Stakeholders should monitor these dynamics as they shape the Shingles Vaccine market outlook.

12 items

1. Executive Summary

2. Shingles Vaccine Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Shingles Vaccine Market Product Outlook & Forecast (2021-2033) Value (USD Million) & Volume (K)

6.1. Global Shingles Vaccine Market Product Outlook & Forecast (2021-2033) Value (USD Million)

6.1.1. Global Shingles Vaccine Market Revenue (USD Million) and CAGR (%) by Type (2020-2032)

6.1.2. Global Shingles Vaccine Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.3. Global Shingles Vaccine Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

6.2. Global Shingles Vaccine Market Product Outlook & Forecast (2021-2033) Volume (K)

6.2.1. Global Shingles Vaccine Market Volume (K) and CAGR (%) by Type (2020-2032)

6.2.2. Global Shingles Vaccine Market Volume (K) and CAGR (%) by Application (2020-2032)

6.2.3. Global Shingles Vaccine Market Volume (K) and CAGR (%) by Region (2020-2032)

7. Global Shingles Vaccine Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Shingles Vaccine Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Type

7.2.3. North America Value (USD Million) (2020-2032) by Application

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Type

7.3.3. South America Value (USD Million) (2020-2032) by Application

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Type

7.4.3. Europe Value (USD Million) (2020-2032) by Application

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Type

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Type

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Application

8. Global Shingles Vaccine Market Breakdown Data By Volume (K) (2020-2032)

8.1. Global Shingles Vaccine Market by: Regions (Volume)

8.1.1. North America

8.1.2. South America

8.1.3. Europe

8.1.4. Middle East & Africa

8.1.5. Asia Pacific

8.2. North America

8.2.1. North America Volume (K) (2020-2032) By Country

8.2.2. North America Volume (K) (2020-2032) by Type

8.2.3. North America Volume (K) (2020-2032) by Application

8.3. South America

8.3.1. South America Volume (K) (2020-2032) By Country

8.3.2. South America Volume (K) (2020-2032) by Type

8.3.3. South America Volume (K) (2020-2032) by Application

8.4. Europe

8.4.1. Europe Volume (K) (2020-2032) By Country

8.4.2. Europe Volume (K) (2020-2032) by Type

8.4.3. Europe Volume (K) (2020-2032) by Application

8.5. Middle East & Africa

8.5.1. Middle East & Africa Volume (K) (2020-2032) By Country

8.5.2. Middle East & Africa Volume (K) (2020-2032) by Type

8.5.3. Middle East & Africa Volume (K) (2020-2032) by Application

8.6. Asia Pacific

8.6.1. Asia Pacific Volume (K) (2020-2032) By Country

8.6.2. Asia Pacific Volume (K) (2020-2032) by Type

8.6.3. Asia Pacific Volume (K) (2020-2032) by Application

9. Global Shingles Vaccine Market Competition by Key Manufacturers

9.1. Global Shingles Vaccine Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

9.2. Player's Concentration

9.2.1. Top 5 Manufacturers

9.2.2. Top 3 Manufacturers

9.3. Market Entropy

Global Shingles Vaccine: Profiled Players Head Office and Area Served

9.4. Key Player Products/Services

9.4.1 Merger & Acquisitions and Expansion Plans

10. Company Profile

10.1. Merck

10.1.1. Company Basic Information and Sales Area

10.1.2. Main Business/Business Overview

10.1.3. Product Portfolio

10.1.4. Financial

10.1.5. Recent Industry Insights

10.1.6. SWOT Analysis

10.2. GlaxoSmithKline

10.2.1. Company Basic Information and Sales Area

10.2.2. Main Business/Business Overview

10.2.3. Product Portfolio

10.2.4. Financial

10.2.5. Recent Industry Insights

10.2.6. SWOT Analysis

11. Methodology/Research Approach

11.1. Research Programs/Material Type

11.2. Market Size Estimation

11.3. Market Breakdown and Data Triangulation

12. Data Sources

12.1. Secondary Sources

12.2. Primary Sources

List of Figures

40 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Shingles Vaccine Market

Figure 4: Global Shingles Vaccine Market: Drivers

Figure 5: Global Shingles Vaccine Market: Challenges

Figure 6: Global Shingles Vaccine Market: Trends

Figure 7: Global Shingles Vaccine Market: Opportunity

Figure 8: Global Shingles Vaccine Market: Restraint

Figure 9: Global Shingles Vaccine Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Type

Figure 11: Global Market Share (%) By Type (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Application

Figure 13: Global Market Share (%) By Application (2024)

Figure 14: Global Market Volume (K) (2020-2024) By Type

Figure 15: Global Market Share (%) By Type (2024)

Figure 16: Global Market Volume (K) (2020-2024) By Application

Figure 17: Global Market Share (%) By Application (2024)

Figure 18: Global Shingles Vaccine Market Value (USD Million) By Region

Figure 19: Global Shingles Vaccine Market Share (%) By: Regions (2024)

Figure 20: Top 5 Manufacturers

Figure 21: Top 3 Manufacturers

Figure 22: Global Market Value (USD Million) (2025-2032) By Type

Figure 23: Global Market Share (%) By Type (2032)

Figure 24: Global Market Value (USD Million) (2025-2032) By Application

Figure 25: Global Market Share (%) By Application (2032)

Figure 26: Global Shingles Vaccine Market Value (USD Million) By Region

Figure 27: Global Shingles Vaccine Market Share (%) By: Regions (2032)

Figure 28: Global Shingles Vaccine Market Volume (K) By Region

Figure 29: Global Shingles Vaccine Market Share (%) By: Regions (2024)

Figure 30: Top 5 Manufacturers

Figure 31: Top 3 Manufacturers

Figure 32: Global Market Volume (K) (2025-2032) By Type

Figure 33: Global Market Share (%) By Type (2032)

Figure 34: Global Market Volume (K) (2025-2032) By Application

Figure 35: Global Market Share (%) By Application (2032)

Figure 36: Global Shingles Vaccine Market Value (USD Million) By Region

Figure 37: Global Shingles Vaccine Market Share (%) By: Regions (2032)

Figure 38: Global Shingles Vaccine Market Volume (K) By Region

Figure 39: Global Shingles Vaccine Market Share (%) By: Regions (2032)

Figure 40: Data Triangulation

List of Tables

99 items

Table 1: Market Segmentation Analysis

Table 2: Global Shingles Vaccine Revenue (USD Million) And Cagr (%) By Type (2020-2032)

Table 3: Global Shingles Vaccine Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 4: Global Shingles Vaccine Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Type

Table 6: Global Market Share (%) By Type (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Application

Table 8: Global Market Share (%) By Application (2024)

Table 9: Global Market Volume (K) (2020-2024) By Type

Table 10: Global Market Share (%) By Type (2024)

Table 11: Global Market Volume (K) (2020-2024) By Application

Table 12: Global Market Share (%) By Application (2024)

Table 13: Global Shingles Vaccine Market Value (USD Million) By Region

Table 14: Global Shingles Vaccine Market Share (%) By Region

Table 15: North America Market Value (USD Million) (2020-2024) By Country

Table 16: North America Market Value (USD Million) (2020-2024) By Type

Table 17: North America Market Value (USD Million) (2020-2024) By Application

Table 18: Europe Market Value (USD Million) (2020-2024) By Country

Table 19: Europe Market Value (USD Million) (2020-2024) By Type

Table 20: Europe Market Value (USD Million) (2020-2024) By Application

Table 21: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 22: Asia Pacific Market Value (USD Million) (2020-2024) By Type

Table 23: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 24: South America Market Value (USD Million) (2020-2024) By Country

Table 25: South America Market Value (USD Million) (2020-2024) By Type

Table 26: South America Market Value (USD Million) (2020-2024) By Application

Table 27: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 28: Middle East & Africa Market Value (USD Million) (2020-2024) By Type

Table 29: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 30: Global Shingles Vaccine Market Volume (K) By Region

Table 31: Global Shingles Vaccine Market Share (%) By Region

Table 32: North America Market Volume (K) (2020-2024) By Country

Table 33: North America Market Volume (K) (2020-2024) By Type

Table 34: North America Market Volume (K) (2020-2024) By Application

Table 35: Europe Market Volume (K) (2020-2024) By Country

Table 36: Europe Market Volume (K) (2020-2024) By Type

Table 37: Europe Market Volume (K) (2020-2024) By Application

Table 38: Asia Pacific Market Volume (K) (2020-2024) By Country

Table 39: Asia Pacific Market Volume (K) (2020-2024) By Type

Table 40: Asia Pacific Market Volume (K) (2020-2024) By Application

Table 41: South America Market Volume (K) (2020-2024) By Country

Table 42: South America Market Volume (K) (2020-2024) By Type

Table 43: South America Market Volume (K) (2020-2024) By Application

Table 44: Middle East & Africa Market Volume (K) (2020-2024) By Country

Table 45: Middle East & Africa Market Volume (K) (2020-2024) By Type

Table 46: Middle East & Africa Market Volume (K) (2020-2024) By Application

Table 47: Global Shingles Vaccine Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 48: Global Shingles Vaccine Market: Profiled Players Head Office And Area Served

Table 49: Key Players Global Shingles Vaccine Market:

Table 50: Mergers & Acquisitions, Expansion Plans

Table 51: Merck Basic Information And Sales Area

Table 52: Merck. Products Portfolio

Table 53: GlaxoSmithKline Basic Information And Sales Area

Table 54: GlaxoSmithKline. Products Portfolio

Table 55: Global Market Value (USD Million) (2025-2032) By Type

Table 56: Global Market Share (%) By Type (2032)

Table 57: Global Market Value (USD Million) (2025-2032) By Application

Table 58: Global Market Share (%) By Application (2032)

Table 59: Global Market Volume (K) (2025-2032) By Type

Table 60: Global Market Share (%) By Type (2032)

Table 61: Global Market Volume (K) (2025-2032) By Application

Table 62: Global Market Share (%) By Application (2032)

Table 63: Global Shingles Vaccine Market Value (USD Million) By Region

Table 64: Global Shingles Vaccine Market Share (%) By Region (2025-2032)

Table 65: North America Market Value (USD Million) (2025-2032) By Country

Table 66: North America Market Value (USD Million) (2025-2032) By Type

Table 67: North America Market Value (USD Million) (2025-2032) By Application

Table 68: Europe Market Value (USD Million) (2025-2032) By Country

Table 69: Europe Market Value (USD Million) (2025-2032) By Type

Table 70: Europe Market Value (USD Million) (2025-2032) By Application

Table 71: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 72: Asia Pacific Market Value (USD Million) (2025-2032) By Type

Table 73: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 74: South America Market Value (USD Million) (2025-2032) By Country

Table 75: South America Market Value (USD Million) (2025-2032) By Type

Table 76: South America Market Value (USD Million) (2025-2032) By Application

Table 77: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 78: Middle East & Africa Market Value (USD Million) (2025-2032) By Type

Table 79: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 80: Global Shingles Vaccine Market Volume (K) By Region

Table 81: Global Shingles Vaccine Market Share (%) By Region (2025-2032)

Table 82: North America Market Volume (K) (2025-2032) By Country

Table 83: North America Market Volume (K) (2025-2032) By Type

Table 84: North America Market Volume (K) (2025-2032) By Application

Table 85: Europe Market Volume (K) (2025-2032) By Country

Table 86: Europe Market Volume (K) (2025-2032) By Type

Table 87: Europe Market Volume (K) (2025-2032) By Application

Table 88: Asia Pacific Market Volume (K) (2025-2032) By Country

Table 89: Asia Pacific Market Volume (K) (2025-2032) By Type

Table 90: Asia Pacific Market Volume (K) (2025-2032) By Application

Table 91: South America Market Volume (K) (2025-2032) By Country

Table 92: South America Market Volume (K) (2025-2032) By Type

Table 93: South America Market Volume (K) (2025-2032) By Application

Table 94: Middle East & Africa Market Volume (K) (2025-2032) By Country

Table 95: Middle East & Africa Market Volume (K) (2025-2032) By Type

Table 96: Middle East & Africa Market Volume (K) (2025-2032) By Application

Table 97: Research Programs/Design For This Report

Table 98: Key Data Information From Secondary Sources

Table 99: Key Data Information From Primary Sources

FAQs

1. What is the current Shingles Vaccine market size?

The Shingles Vaccine market size was estimated at roughly USD 1.2 billion in 2023, reflecting strong demand for adult immunizations across mature economies. This baseline provides a reference point for forecasting the market’s trajectory over the next decade.

2. How fast is the market expected to grow?

Analysts project a compound annual growth rate of about 5.5 % between 2024 and 2032, pushing the market toward a valuation near USD 1.8 billion by 2032. This future outlook reflects expanding vaccination recommendations and demographic shifts toward older age groups.

3. What are the primary drivers of market expansion?

Key drivers include an aging global population, rising shingles incidence, inclusion of Shingles vaccines in national adult immunization schedules, and heightened physician awareness. Additionally, strong clinical data on Shingrix’s efficacy fuels demand across both public and private payers.

4. What challenges could hinder market growth?

Challenges encompass vaccine hesitancy among older adults, pricing scrutiny from health insurers, limited supply in emerging markets, and competition from newer platforms such as mRNA candidates. Logistical hurdles in cold‑chain management also constrain rollout in low‑resource settings.

5. Which regions lead the Shingles Vaccine market?

North America remains the dominant region, driven by robust reimbursement frameworks and high awareness, while Europe follows closely with strong public‑health initiatives. Asia‑Pacific is emerging rapidly, propelled by expanding geriatric populations and increasing government immunization budgets.

6. Who are the top companies in this market?

The market is led by GSK’s Shingrix, which commands the largest share, followed by Merck’s Zostavax legacy product. Pfizer and Sanofi are advancing next‑generation candidates, while smaller biotech firms focus on novel adjuvant and delivery technologies.

7. What future opportunities exist for stakeholders?

Future opportunities arise from combination vaccines that pair shingles protection with influenza or COVID‑19 shots, expansion of adult vaccination programs in developing economies, and digital health platforms that improve adherence. These trends could unlock new revenue streams.

8. How is technology influencing the market?

Advances in recombinant subunit technology, novel adjuvants, and mRNA research are reshaping vaccine design, offering higher efficacy and shorter production cycles. Cold‑chain innovations and thermostable formulations further enhance distribution, especially in remote or low‑infrastructure regions.

9. What does the regulatory landscape look like?

Regulatory pathways involve FDA and EMA approvals based on robust phase‑III data, with accelerated routes available for high‑risk groups. Post‑marketing surveillance and real‑world effectiveness studies are increasingly required, influencing launch timelines and market access strategies.

Contact for Full Report

Loading report content...

Shingles Vaccine Growth Trends & Strategic Outlook 2033

Market Snapshot

Shingles Vaccine Market Overview

Report Overview

Market Dynamics

Market Segmentation

Regional Insights

Competitive Landscape

Market Ecosystem

Recent Industry Insights

Analyst Overview

Shingles Vaccine Segmentation

Shingles Vaccine Segmentation by Geography

Table of Contents

Table of Contents

List of Figures

List of Tables

FAQs

1. What is the current Shingles Vaccine market size?

2. How fast is the market expected to grow?

3. What are the primary drivers of market expansion?

4. What challenges could hinder market growth?

5. Which regions lead the Shingles Vaccine market?

6. Who are the top companies in this market?

7. What future opportunities exist for stakeholders?

8. How is technology influencing the market?

9. What does the regulatory landscape look like?

Methodology

Step 1 - Selecting Representative Samples from the Population

Step 2 - Methods for Estimating Market Size (Value, Volume & Price*)

Step 3 - Information Sources

📘 Direct Research

📚 Indirect Research

Step 4 - Data Validation & Triangulation

Market Snapshot

Shingles Vaccine Market Overview

Report Overview

Market Dynamics

Market Segmentation

Regional Insights

Competitive Landscape

Market Ecosystem

Recent Industry Insights

Analyst Overview

Shingles Vaccine Segmentation

Shingles Vaccine Segmentation by Geography

Table of Contents

Table of Contents

List of Figures

List of Tables

FAQs

1. What is the current Shingles Vaccine market size?

2. How fast is the market expected to grow?

3. What are the primary drivers of market expansion?

4. What challenges could hinder market growth?

5. Which regions lead the Shingles Vaccine market?

6. Who are the top companies in this market?

7. What future opportunities exist for stakeholders?

8. How is technology influencing the market?

9. What does the regulatory landscape look like?

Methodology

Step 1 - Selecting Representative Samples from the Population

Step 2 - Methods for Estimating Market Size (Value, Volume & Price*)

Step 3 - Information Sources

📘 Direct Research

📚 Indirect Research

Step 4 - Data Validation & Triangulation